Clinical Trials Browser

Phase 1/2 × Breast Neoplasms × Anastrozole × Clear all

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Phase 1/2 Active not recruiting

44 enrolled

Breast

Breast Diseases, Breast Neoplasms

NCT01216176 2025-01-08

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Phase 1/2 Completed

71 enrolled 15 charts

Breast

Breast Neoplasms

NCT03481998 2023-11-21

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Phase 1/2 Completed

104 enrolled

Breast

Breast Neoplasms

NCT01791985 2022-08-22

RADICAL

Phase 1/2 Completed

52 enrolled 17 charts

Breast

Breast Neoplasms

NCT01484041 2018-02-09

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

Breast

Breast Neoplasms

NCT00217399 2014-05-28

Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 1/2 Completed

35 enrolled 9 charts

Breast

Breast Neoplasms

Clinical Trials

PIKALO-1

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

RADICAL

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer